Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Alfred Callahan; Pierre Amarenco; Larry B Goldstein; Henrik Sillesen; Mike Messig; Gregory P Samsa; Irfan Altafullah; Lucy Y Ledbetter; Mary J MacLeod; Russell Scott; Michael Hennerici; Justin A Zivin; K Michael A Welch; SPARCL Investigators

doi:10.1001/archneurol.2011.146

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Alfred Callahan, Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Mike Messig, Gregory P Samsa, Irfan Altafullah, Lucy Y Ledbetter, Mary J MacLeod, Russell Scott, Michael Hennerici, Justin A Zivin, K Michael A Welch, SPARCL Investigators

Applied Medicine

Research output: Contribution to journal › Article › peer-review

84 Citations (Scopus)

Abstract

To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).

Original language	English
Pages (from-to)	1245-1251
Number of pages	7
Journal	Archives of Neurology
Volume	68
Issue number	10
DOIs	https://doi.org/10.1001/archneurol.2011.146
Publication status	Published - 2011

Keywords

Adult
Aged
Aged, 80 and over
Cardiovascular Physiological Processes
Cholesterol
Confidence Intervals
Diabetes Mellitus, Type 2
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ischemic Attack, Transient
Lipoproteins, HDL
Lipoproteins, LDL
Male
Metabolic Syndrome X
Middle Aged
Proportional Hazards Models
Pyrroles
Retrospective Studies
Risk Factors
Stroke
Triglycerides
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/archneurol.2011.146

Fingerprint

Dive into the research topics of 'Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial'. Together they form a unique fingerprint.

Cite this

Callahan, A., Amarenco, P., Goldstein, L. B., Sillesen, H., Messig, M., Samsa, G. P., Altafullah, I., Ledbetter, L. Y., MacLeod, M. J., Scott, R., Hennerici, M., Zivin, J. A., Welch, K. M. A., & SPARCL Investigators (2011). Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Archives of Neurology, 68(10), 1245-1251. https://doi.org/10.1001/archneurol.2011.146

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. / Callahan, Alfred; Amarenco, Pierre; Goldstein, Larry B et al.
In: Archives of Neurology, Vol. 68, No. 10, 2011, p. 1245-1251.

Research output: Contribution to journal › Article › peer-review

Callahan, A, Amarenco, P, Goldstein, LB, Sillesen, H, Messig, M, Samsa, GP, Altafullah, I, Ledbetter, LY, MacLeod, MJ, Scott, R, Hennerici, M, Zivin, JA, Welch, KMA & SPARCL Investigators 2011, 'Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial', Archives of Neurology, vol. 68, no. 10, pp. 1245-1251. https://doi.org/10.1001/archneurol.2011.146

Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Archives of Neurology. 2011;68(10):1245-1251. doi: 10.1001/archneurol.2011.146

Callahan, Alfred ; Amarenco, Pierre ; Goldstein, Larry B et al. / Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome : secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. In: Archives of Neurology. 2011 ; Vol. 68, No. 10. pp. 1245-1251.

@article{0bb61f0f753f4959b60f1a617cf881e2,

title = "Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial",

abstract = "To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).",

keywords = "Adult, Aged, Aged, 80 and over, Cardiovascular Physiological Processes, Cholesterol, Confidence Intervals, Diabetes Mellitus, Type 2, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ischemic Attack, Transient, Lipoproteins, HDL, Lipoproteins, LDL, Male, Metabolic Syndrome X, Middle Aged, Proportional Hazards Models, Pyrroles, Retrospective Studies, Risk Factors, Stroke, Triglycerides, Young Adult",

author = "Alfred Callahan and Pierre Amarenco and Goldstein, {Larry B} and Henrik Sillesen and Mike Messig and Samsa, {Gregory P} and Irfan Altafullah and Ledbetter, {Lucy Y} and MacLeod, {Mary J} and Russell Scott and Michael Hennerici and Zivin, {Justin A} and Welch, {K Michael A} and {SPARCL Investigators}",

year = "2011",

doi = "10.1001/archneurol.2011.146",

language = "English",

volume = "68",

pages = "1245--1251",

journal = "Archives of Neurology",

issn = "0375-8540",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome

T2 - secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

AU - Callahan, Alfred

AU - Amarenco, Pierre

AU - Goldstein, Larry B

AU - Sillesen, Henrik

AU - Messig, Mike

AU - Samsa, Gregory P

AU - Altafullah, Irfan

AU - Ledbetter, Lucy Y

AU - MacLeod, Mary J

AU - Scott, Russell

AU - Hennerici, Michael

AU - Zivin, Justin A

AU - Welch, K Michael A

AU - SPARCL Investigators

PY - 2011

Y1 - 2011

N2 - To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).

AB - To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Cardiovascular Physiological Processes

KW - Cholesterol

KW - Confidence Intervals

KW - Diabetes Mellitus, Type 2

KW - Female

KW - Heptanoic Acids

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Ischemic Attack, Transient

KW - Lipoproteins, HDL

KW - Lipoproteins, LDL

KW - Male

KW - Metabolic Syndrome X

KW - Middle Aged

KW - Proportional Hazards Models

KW - Pyrroles

KW - Retrospective Studies

KW - Risk Factors

KW - Stroke

KW - Triglycerides

KW - Young Adult

U2 - 10.1001/archneurol.2011.146

DO - 10.1001/archneurol.2011.146

M3 - Article

C2 - 21670382

SN - 0375-8540

VL - 68

SP - 1245

EP - 1251

JO - Archives of Neurology

JF - Archives of Neurology

IS - 10

ER -